美股異動丨諾和諾德升超2.5% 據稱其減肥藥對12歲以下兒童安全有效
諾和諾德(NVO.US)升超2.5%,報133.035美元。消息面上,根據諾和諾德資助的一項新研究顯示,該公司的一種減肥藥對6歲兒童安全有效,這為利拉魯肽(Liraglutide)成為首款用於該年齡組兒童的肥胖症治療藥物鋪平了道路。試驗結果表明,使用諾和諾德減肥注射筆(Saxenda)僅一年多的6至12歲兒童,與服用安慰劑的兒童相比,體重指數下降了7.4%。這一實驗包括了82名兒童,他們之前已接受過生活方式干預治療,但沒有取得什麼效果。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.